BMS-986202 is a novel Tyk2 inhibitor,binding to Tyk2 JH2,showing efficacies for IL-23-driven acanthosis,anti-CD40-induced colitis,and spontaneous lupus.
Bucinnazine is a potent and selective agonist of μ-opioid receptor (MOR) with relatively low affinity for the δ-opioid receptor and the κ-opioid receptor.